Literature DB >> 22509823

Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier.

Ziqiang Cheng1, Houfu Liu, Na Yu, Fei Wang, Gang An, Yan Xu, Qian Liu, Chen-bing Guan, Andrew Ayrton.   

Abstract

OATP1A2 is expressed in the luminal membrane of human blood-brain barrier (BBB). The human tissue with the highest OATP1A2 mRNA expression is the brain. We have established a robust BacMam2-OATP1A2 transduced HEK293 system. Among the 36 central nervous system (CNS) marketed drugs tested, hydrophilic triptans, 5-HT(1B/1D) receptor agonists for the treatment of migraine attacks, were identified as OATP1A2 substrates. Kinetics (K(m) and V(max)) were determined for six marketed triptans. Structure-activity relationship (SAR) obtained from 18 triptan structural analogs revealed that the positively charged basic amine atom was essential for efficient OATP1A2-mediated triptan uptake and uptake rate was in the order of tertiary > secondary > primary. Preliminary quantitative SAR analysis of the triptan analogs demonstrated positive correlation between OATP1A2-mediated uptake rate and van der Waals volume (vdw_vol). OATP1A2 was specifically expressed on the apical side of MDCKII monolayer after BacMam2-OATP1A2 transduction and can facilitate transport of triptans across the MDCKII monolayer from apical to basolateral side. Involvement of OATP1A2 for brain penetration of triptans in human requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22509823     DOI: 10.3109/00498254.2012.675455

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

Review 1.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 2.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Protective Roles of N-acetyl Cysteine and/or Taurine against Sumatriptan-Induced Hepatotoxicity.

Authors:  Javad Khalili Fard; Hossein Hamzeiy; Mohammadreza Sattari; Mohammad Ali Eghbal
Journal:  Adv Pharm Bull       Date:  2016-12-22

5.  Morphine and the blood-brain barrier: diffusion, uptake, or efflux?

Authors:  Karsten Bartels; Konrad Meissner
Journal:  Can J Anaesth       Date:  2017-07-18       Impact factor: 5.063

6.  PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability.

Authors:  Jian Zheng; Ting Chan; Florence Shin Gee Cheung; Ling Zhu; Michael Murray; Fanfan Zhou
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

7.  Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.

Authors:  Karissa E Cottier; Emily A Galloway; Elisa C Calabrese; Margaret E Tome; Erika Liktor-Busa; John Kim; Thomas P Davis; Todd W Vanderah; Tally M Largent-Milnes
Journal:  eNeuro       Date:  2018-07-16

8.  Sex-specific differences in organic anion transporting polypeptide 1a4 (Oatp1a4) functional expression at the blood-brain barrier in Sprague-Dawley rats.

Authors:  Hrvoje Brzica; Wazir Abdullahi; Bianca G Reilly; Patrick T Ronaldson
Journal:  Fluids Barriers CNS       Date:  2018-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.